Skip to main content
Log in

Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

We assessed the rate of detection rate of recurrent prostate cancer by PET/CT using anti-3-18F-FACBC, a new synthetic amino acid, in comparison to that using 11C-choline as part of an ongoing prospective single-centre study.

Methods

Included in the study were 15 patients with biochemical relapse after initial radical treatment of prostate cancer. All the patients underwent anti-3-18F-FACBC PET/CT and 11C-choline PET/CT within a 7-day period. The detection rates using the two compounds were determined and the target–to-background ratios (TBR) of each lesion are reported.

Results

No adverse reactions to anti-3-18F-FACBC PET/CT were noted. On a patient basis, 11C-choline PET/CT was positive in 3 patients and negative in 12 (detection rate 20 %), and anti-3-18F-FACBC PET/CT was positive in 6 patients and negative in 9 (detection rate 40 %). On a lesion basis, 11C-choline detected 6 lesions (4 bone, 1 lymph node, 1 local relapse), and anti-3-18F-FACBC detected 11 lesions (5 bone, 5 lymph node, 1 local relapse). All 11C-choline-positive lesions were also identified by anti-3-18F-FACBC PET/CT. The TBR of anti-3-18F-FACBC was greater than that of 11C-choline in 8/11 lesions, as were image quality and contrast.

Conclusion

Our preliminary results indicate that anti-3-18F-FACBC may be superior to 11C-choline for the identification of disease recurrence in the setting of biochemical failure. Further studies are required to assess efficacy of anti-3-18F-FACBC in a larger series of prostate cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Shoup TM, Olson J, Hoffman JM, Votaw J, Eshima D, Eshima L, et al. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999;40:331–8.

    PubMed  CAS  Google Scholar 

  2. Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18 FFACBC in humans. J Nucl Med. 2007;48(6):1017–20.

    Article  PubMed  CAS  Google Scholar 

  3. Oka S, Okudaira H, Yoshida Y, Schuster DM, Goodman MM, Shirakami Y. Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells. Nucl Med Biol. 2012;39(1):109–19.

    Article  PubMed  CAS  Google Scholar 

  4. Okudaira H, Shikano N, Nishii R, Miyagi T, Yoshimoto M, Kobayashi M, et al. Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med. 2011;52(5):822–9.

    Article  PubMed  CAS  Google Scholar 

  5. Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1- amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48(1):56–63.

    PubMed  CAS  Google Scholar 

  6. Sörensen J, Owenius R, Lax M, Johansson S. Regional distribution and kinetics of [(18)F]fluciclovine (anti-[ (18)F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(3):394–402.

    Article  PubMed  Google Scholar 

  7. Schuster DM, Savir-Baruch D, Nieh P, Master VA, Halkar RK, Rossi PJ, et al. Detection of recurrent prostate carcinoma with anti-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology. 2011;259:852–61.

    Article  PubMed  Google Scholar 

  8. Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A, et al. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol. 2010;184(3):938–43.

    Article  PubMed  Google Scholar 

  9. McConathy J, Voll RJ, Yu W, Crowe RJ, Goodman MM. Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. Appl Radiat Isot. 2003;58(6):657–66.

    Article  PubMed  CAS  Google Scholar 

  10. Pascali C, Bogni A, Itawa R, Cambiè M, Bombardieri E. [11C]Methylation on a C18 Sep-Pak cartridge: a convenient way to produce [N-methyl-11C]choline. J Labelled Comp Radiopharm. 2000;49:195–203.

    Article  Google Scholar 

  11. Iatrou M, Ross SG, Manjeshwar RM, Stearns CW. A fully 3D iterative image reconstruction algorithm incorporating data corrections. Nuclear Science Symposium Conference Record, 2004, IEEE. 2004;4:2493–7.

    Google Scholar 

  12. Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999;54(5):884–90.

    Article  PubMed  CAS  Google Scholar 

  13. Beissert M, Lorenz R, Gerharz EW. Rational imaging in locally advanced prostate cancer. Urologe A. 2008;47(11):1405–16.

    Article  PubMed  CAS  Google Scholar 

  14. Reske SN, Blumstein NM, Glatting G. PET and PET/CT in relapsing prostate carcinoma. Urologe A. 2006;45(10):1240, 1242–4, 1246–8, 1250.

    Article  PubMed  CAS  Google Scholar 

  15. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910–4.

    Article  PubMed  CAS  Google Scholar 

  16. Shuster JR, Lance RS, Troyer DA. Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue. BMC Clin Pathol. 2011;11:14.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Cristina Nanni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nanni, C., Schiavina, R., Boschi, S. et al. Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. Eur J Nucl Med Mol Imaging 40 (Suppl 1), 11–17 (2013). https://doi.org/10.1007/s00259-013-2373-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-013-2373-3

Keywords

Navigation